Chi-Med lines up next two candidates for regulatory filings

31 July 2019

Hotly-tipped Hong Kong-based biotech Hutchison China MediTech (AIM: HCM), mostly known as Chi-Med, has said it expects to file for a new cancer drug this year, the second after its approved therapy Elunate (fruquintinib).

Chi-Med launched Elunate in 2018, in collaboration with Eli Lilly (NYSE: LLY), to treat certain people with metastatic colorectal cancer (CRC) that have been previously treated with chemotherapy.

Given that there is a high level of competition for VEGF blockers in China, with five other small molecules on the market, it is thought that the firm’s other late-stage candidates could have more of an impact than Elunate.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK